Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Should orlistat be avoided in patients with a history of kidney stones?
Related Questions
How do you counsel patients on the use of compounded weight loss medications?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
Do you recommend non-bypass bariatric surgeries over intestinal bypass procedures for kidney transplant-eligible candidates to prevent oxalate nephropathy, given the higher risk of kidney oxalate deposition with intestinal bypass?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?
How do you approach the use of GLP-1 receptor agonists for the management of patients with metabolically healthy obesity?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
When do you consider using setmelanotide for treatment of hypothalamic obesity?
